Lambert-eaton Myasthenic Syndrome
📧 Sign up to get email alerts when something new happens for Lambert-eaton Myasthenic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases [Phase 2]
Phase 2 clinical trial investigating autologous stem cell transplant for neurologic autoimmune diseases is currently active but not recruiti…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
Development and validation of the FBIndex, a tool to assess falls risk in patients with various neuromuscular disorders.
-
CLINICAL_TRIALS research · 2025-08-01Clinical Trial Update: A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)
This clinical trial will evaluate the incidence of clinically suspicious Lambert-Eaton myasthenic syndrome in subjects diagnosed with small …
-
CLINICAL_TRIALS approval · 2025-03-26Clinical Trial Update: Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Amifampridine phosphate has received marketing approval for Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndrome. This updat…
-
EMA approval · 2024-12-18EMA Authorised: Firdapse (previously Zenas) (amifampridine) — SERB SA
The European Medicines Agency authorised Firdapse (amifampridine) for the treatment of Lambert-Eaton Myasthenic Syndrome. The marketing auth…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis
This is an observational clinical trial using environmental and wearable sensors to study Myasthenia Gravis and related myasthenic condition…
-
FDA approval · 2024-05-30FDA Approved: FIRDAPSE — Supplemental Application (Catalyst Pharmaceuticals, Inc.)
The FDA approved a supplemental application for FIRDAPSE (amifampridine phosphate) from Catalyst Pharmaceuticals. The approval indicates a m…
-
FDA approval · 2023-05-15FDA Approved: FIRDAPSE — Supplemental Application (Catalyst Pharmaceuticals, Inc.)
The FDA approved a supplemental application for FIRDAPSE (amifampridine phosphate) submitted by Catalyst Pharmaceuticals, Inc. The approval …
-
EMA approval · 2022-05-24EMA Authorised: Amifampridine SERB (amifampridine phosphate) — SERB SA
European Medicines Agency authorises amifampridine phosphate (SERB) for various neuromuscular and autoimmune conditions, with Lambert-Eaton …
-
FDA approval · 2021-03-01FDA Approved: FIRDAPSE — Supplemental Application (Catalyst Pharmaceuticals, Inc.)
The FDA approved a supplemental application for FIRDAPSE (amifampridine phosphate) from Catalyst Pharmaceuticals. The action modifies the re…
-
CLINICAL_TRIALS trial_result · 2019-05-21Clinical Trial Update: Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) [Phase 2]
Phase 2 trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2018-12-24Clinical Trial Update: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) [Phase 3]
Phase 3 trial evaluating amifampridine phosphate for Lambert-Eaton Myasthenic Syndrome has been completed with results posted in 2018.
-
FDA approval · 2018-11-28FDA Approved: FIRDAPSE — Original Application (Catalyst Pharmaceuticals, Inc.)
FDA approved FIRDAPSE (amifampridine phosphate) in this original application for Lambert-Eaton myasthenic syndrome, marking the drug's initi…
-
CLINICAL_TRIALS trial_result · 2018-01-04Clinical Trial Update: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) [Phase 3]
Phase 3 study of amifampridine phosphate in Lambert-Eaton myasthenic syndrome has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-07-11Clinical Trial Update: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome [Phase 2]
A Phase 2 clinical trial evaluating the effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome has completed and posted r…
-
CLINICAL_TRIALS withdrawal · 2016-07-20Clinical Trial Update: Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Clinical trial update notes that a study evaluating 3,4-diaminopyridine for Lambert-Eaton myasthenic syndrome is no longer available.
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome [NA]
A randomized study evaluating the use of 3,4-Diaminopyridine for Lambert-Eaton myasthenic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2013-07-18Clinical Trial Update: Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
A clinical trial evaluating 3,4-DAP for Lambert-Eaton Myasthenic Syndrome is no longer available.